Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

Immunomedics Inc. (Nasdaq: IMMU)

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel DOCK-AND-LOCK™ (DNL™) method with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 227 active patents in the United States and more than 400 foreign patents, protects our product candidates and technologies. Our strength in intellectual property has resulted in the top-10 ranking in the 2012 IEEE Spectrum Patent Power Scorecards in the Biotechnology and Pharmaceuticals category. *

 

Period Start 1982-01-01 established
  Group Gilead Sciences (Group)
Products Industry antibody-drug conjugate (ADC)
  Industry 2 Trodelvy™
     
  Street 300 American Road
  City 07950 Morris Plains, NJ
  Tel +1-973-605-8200
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: 
     
   
Record changed: 2021-01-05

Advertisement

Picture [iito] Made Without Love 650x80px

More documents for Gilead Sciences (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC B Preview Download 650x300px




» top